Wegovy and Blood Pressure: How Much It Drops
The Wegovy label names hypotension as a reported side effect but gives no trial rate for it.
- In the label
- Listed, no rate given
- Label term
- hypotension
Wegovy facts at a glance
Its half-life is about 1 week: after 7 d, half of it is gone. About 3% is left once five half-lives have passed (35 d).
In STEP 1 at 68 weeks, 14.9% of body weight was lost, compared with 2.4% on placebo.
In US dollars, monthly prices include the list price and self-pay offers. Both were read from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.
What the Wegovy label lists instead
The Wegovy label does not give a rate for blood pressure. Five side effects appear most often in the list, with rates for each.
| Side effect | Placebo | Wegovy 2.4 mg | More than placebo |
|---|---|---|---|
| Nausea | 16% | 44% | +28 points |
| Diarrhea | 16% | 30% | +14 points |
| Vomiting | 6% | 24% | +18 points |
| Constipation | 11% | 24% | +13 points |
| Abdominal Pain | 10% | 20% | +10 points |
From: Wegovy label (DailyMed).
Comparing Wegovy blood pressure results with other GLP-1s
Each label covers its own trials, which included different groups of people. Use this as a rough guide.
| Medicine | Highest rate in the label | Dose group | Placebo | People in the trials |
|---|---|---|---|---|
 Zepbound | 2% | 15 mg | 0% | Adults with obesity or overweight (weight management) |
| Wegovy | Listed, no rate given | – | – | – |
 Foundayo | Listed, no rate given | – | – | – |
 Saxenda | Listed, no rate given | – | – | – |
 Ozempic | Not listed | – | – | – |
 Rybelsus | Not listed | – | – | – |
 Mounjaro | Not listed | – | – | – |
 Trulicity | Not listed | – | – | – |
 Victoza | Not listed | – | – | – |
| Byetta | Not listed | – | – | – |
From: Zepbound label (DailyMed).
Source: FDA label (DailyMed).
Guidance from the Wegovy label
Here, the label mentions blood pressure in these exact words:
“Adverse reactions related to hypotension (hypotension, orthostatic hypotension, and decreased blood pressure) were reported in 1.3% of WEGOVY-treated adult patients versus 0.4% of placebo-treated patients”
Source: FDA label (DailyMed).